The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Guo noted that previous research suggested that GLP-1RAs — a drug also used to treat obesity and kidney disease ... Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...